Focus on Diabetes Care

Back to articles

New antidiabetic agent results in improved CV outcomes

KEY POINT

Addition of empagliflozin (Jardiance—Boehringer Ingelheim, Eli Lilly) to standard of care therapy in patients with type 2 diabetes at high risk for cardiovascular (CV) events resulted in a reduced risk of adverse CV outcomes.

SOURCES

Zinman B et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;[Epub ahead of print].